A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer¿s Disease Therapy in Patients with Moderate Severity Alzheimer¿s Disease